Friday, October 30, 2009

The end of speculation?

From The Elliott Wave Financial Forecast, October 30, 2009:

"....The recent strong downside breadth as well as the downside leadership from the higher-beta secondary indexes indicate that the most intense phase of the bear market to date is starting.....This time, all of the more speculative stock indexes, including the S&P Small Cap 600, the Russell 2000, the Value Line, and the NASDAQ, are charging ahead on the downside; this old fashioned stock behavior is probably an early sign that the optimistic bias of the past decade is finally about to yield."

My charts below support this premise:

Weekly Sell Signal

RUT - Daily Sell Signal

RUT - Hourly Sell Signal

TZA - Daily Buy Signal

TZA is the bearish triple beta inverse ETF for the Russell 2000


SPX short-term sell

SPX Hourly
Mechanical Sell Signal from Advanced GET
SPX should drop 20+ points to under 1040



ERY is a 3X leveraged bearish energy ETF. It trades fast and furious, but if you get it right, the returns are worth the risk:



Note a familiar FBS pattern


Thursday, October 29, 2009

FBS patterns

All of the following charts are exhibiting almost identical False Bar Stochastic patterns. Based on this pattern, the next few days are crucial for the Intermediate trend. Either prices fall back into an extended down trend, or, the market bounce from today will continue until prices get overbought toward the middle of next week. This observation may not answer how to trade through this period, but at least it provides some backdrop and perspective from which to deal with the days ahead.

On Sells, for now


Even if still Long, most are just another weak day away from triggering back Short

NNVC 90 minute

Note how the FBS has entered Trend mode


Quick take

Sell signal still in place on Daily charts, more later if time allows.


Wednesday, October 28, 2009

Only the beginning


NNVC Buy Signal


Interim charts: RUT SPX NDX

Breaking under rising trend lines from March & July lows


Just Charts: ETF's -> Fresh Daily Buys


Just charts Wednesday

Renko SPX Weekly

Renko SPX Daily

SPX Daily

SPX Daily

SPX Hourly


Tuesday, October 27, 2009

Remember this?

Earlier in the year this chart warned of another leg down in the equity markets that would challenge then exceed the March, 2009 lows. While the index rose 65% from early March, this chart kept me from significant participation in the rally. My bad.

Today the SPX is poised to confirm the Wave 5 Sell Signal by a drop through the rising trend line from early March and the BWT & ATR Sell thresholds. Those levels sit at approximately 1065 for the trend line, 1035 for BWT and 1030 for ATR. A confirmation for any of those thresholds requires a Weekly close below those levels.

Note that any such close this week will likely also trigger a False Bar Stochastic Sell Signal.


Monday, October 26, 2009

Monday, monday.....

We finally got our SELL on the Daily SPX chart, basis both Blue Wave and ATR. The next major threshold lower is the upward trending support line from the March, 2009 lows. Once that gets taken out, the fun begins.




One two.......

Russell 30 minute

DJIA 30 minute

Value Line 30 minute



Press Release
Source: NanoViricides, Inc.
On 7:00 am EDT, Monday October 26, 2009

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

The Company announced that it has recently raised more than $4.3M in equity financing. The Company projects that this additional capital should be sufficient for at least 18 months of operations, or beyond December, 2010, at its current burn rate. In addition, as a result of strong and continued success in its anti-viral drug development programs, management believes that the Company has significantly improved access to the capital markets for additional funding that may be needed for financing IND studies.

“We now have four commercially important drugs in our pipeline, and sufficient funds to pursue further development,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “these drugs address a $40 billion market space.” The four commercially important drugs target HIV, all Influenzas, viral diseases of the external Eye, and Herpes Simplex viral infections including cold sores and genital herpes (HSV).

The Company has described the results from its preliminary anti-HIV animal model studies in a standard SCID-hu Thy/Liv mouse model in its annual report (filed on October 13, 2009). The anti-HIV nanoviricide drug candidates were found to be superior to a three-drug cocktail called HAART (for “highly active anti-retroviral therapy”) in all parameters tested. Significantly, the best nanoviricide drug candidate showed HIV-1 viral load reduction that was superior to that of animals treated with the oral HAART three-drug cocktail. This nanoviricide drug candidate also led to a significant increase in the proportion of human T lymphocytes that were positive for both CD4 and CD8 markers (CD4+CD8+ Double Positives or “DP”). This increase in DP human T cells in the nanoviricide treated mice was equal to or better than the oral HAART three-drug cocktail. Loss of human T cells caused by HIV was thus completely reversed by nanoviricide treatment.

Even more significantly the nanoviricide anti-HIV treatment was >25X (or >2,500%) more effective than the oral HAART treatment, on a drug load basis. The nanoviricide achieved these effects at a dosage level of only 150mg/kg, while the total HAART drug dosage was 4,200 mg/kg.

It is very important to note that no adverse events were observed in the nanoviricide treated mice, while the HAART-treated mice exhibited clinical signs of side effects.

The Company believes that HIVCide™ could very well result in a “Functional Cure” for HIV/AIDS, if these preliminary results are confirmed in further animal studies and in human clinical trials. In other words, HIVCide treatment could enable a HIV/AIDS patient to lead a completely disease-free life until an episode of hidden virus awakening from latent reservoirs occurs. HIV hides in immune cells forming latent reservoirs. It is widely believed in the scientific community that if these latent reservoirs could be wiped out then a complete cure for HIV/AIDS is possible.

The Company also detailed that it is now developing a single anti-influenza drug that is expected to be highly effective against all influenzas including swine flu (H1N1/2009), bird flu (H5N1), other pandemic capable highly pathogenic influenza viruses, as well as seasonal influenzas. The Company’s research over the past year enabled it to combine its separate drug programs for highly pathogenic influenzas, bird flu, and seasonal flu into one drug, FluCide™, to treat all influenza variants.

The Company has reported significant progress in its topical nanoviricide eye drops program. This drug is designed to treat most viral infections of the external eye, including adenoviral conjunctivitis (EKC) and herpes keratitis.

The Company also reported that it has successfully added a new anti-HSV drug program to its pipeline this year. The Company‘s topical anti-herpes drug candidate has already demonstrated greater than 10,000-fold (>99.99%, or >4 logs) reduction in virus quantity in cell culture models of HSV-1 infection. Animal model studies of topical and genital herpes are planned.

“We have already established a strong and robust drug pipeline,” said Anil R. Diwan, PhD, President of the Company, adding, “We now plan to focus on filing our first IND application as early as possible.”

About NanoViricides:

NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Sunday, October 25, 2009


There have been a lot of requests for NNVC charts, so the lesson of this Blog is be careful what you ask for. I don't trade NNVC (I am a buy & holder, period), but if I did, this 240 minute chart has a nice combination of sizable winning trades without very many whipsaws. And guess what? It's bullish!

It works for many lower priced stocks. Here is a Daily chart of Gulf Resources, bought here at a 1-4 split adjusted cost of 88c:

GRUS Daily

Another look:

GRUS Weekly

What do these three charts have in common?

(1) Trend following trading systems;
(2) Profits;
(3) No fundamental input whatsoever, no sectors, prospects nor rumors.

Not a bad time to take another look here.


Saturday, October 24, 2009

Five easy pieces

SPX Daily

Big picture perspective

SPX Daily

Closer-up with Monday's Sell triggers

I N T R A - D A Y

SPX 240 minute

Trend line up from Summer Lows

SPX 60 minute

ATR & FBS Confirmation Swing Sells

SPX 13 minute

This 13 minute chart with ATR effectively
traded S&P all last week